SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cacaito who wrote (920)10/11/1999 12:36:00 PM
From: schadenfreude  Read Replies (1) of 1386
 
Cacaito,
Many questions:
Is the 300 trial size large enough for approval. I'm thinking of safety as well as efficacy. So far, this molecule has proven to be very safe, but might the FDA be concerned about that one-in-a-thousand adverse event?

Is Pharmos looking for a private investor (e.g., Icahn, Gates) to finance PIII? The remaining credit line won't last long and I'm very concerned about dilution with the share price at <1 1/2.

>1. They are not willing to risk due to mediocre data.
2. Aviv is not willing to give company away.
3. But they are willing to join later (and pay what Aviv is asking) when more data available.<

I'm very interested in your thoughts on (1). Yes, the drop in the mortality rate was less than hoped for and not statistically significant. However, the probability for approval and large sales is quite high IMO. My take (my hope?) is that Aviv is asking for PIII royalties for PII results. I am quite content to have the company go it alone provided that they can raise the additional capital needed to complete the trial, SOONER rather than later.

BTW, I appreciate your considerable contribution over on the XOMA thread. The truth was apparent for all to see--some just weren't ready to see it, myself included.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News